- Home
- MRNA vs MKL Comparison
MRNA vs MKL Comparison
Compare MRNA & MKL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MRNA | MKL |
|---|---|---|
| Founded | 2010 | 1930 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Property-Casualty Insurers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.7B | 22.2B |
| IPO Year | 2018 | 1999 |
Fundamental Metrics
Financial Performance| Metric | MRNA | MKL |
|---|---|---|
| Price | $137.95 | $1,819.78 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 12 | 1 |
| Target Price | $34.27 | ★ $2,100.00 |
| AVG Volume (30 Days) | ★ 25.3M | 64.0K |
| Earning Date | 05-01-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 21.77 | N/A |
| EPS | N/A | ★ 73.57 |
| Revenue | ★ $19,263,000,000.00 | $15,513,233,000.00 |
| Revenue This Year | $9.36 | N/A |
| Revenue Next Year | $15.43 | $2.26 |
| P/E Ratio | ★ N/A | $24.55 |
| Revenue Growth | ★ 4.29 | N/A |
| 52 Week Low | $22.28 | $1,719.41 |
| 52 Week High | $176.66 | $2,207.59 |
Technical Indicators
Market Signals| Indicator | MRNA | MKL |
|---|---|---|
| Relative Strength Index (RSI) | 63.84 | 40.86 |
| Support Level | $41.01 | $1,772.00 |
| Resistance Level | $176.66 | $1,876.58 |
| Average True Range (ATR) | 13.95 | 26.59 |
| MACD | 5.94 | 0.94 |
| Stochastic Oscillator | 67.07 | 36.41 |
Price Performance
Historical ComparisonAbout MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
About MKL Markel Group Inc.
Markel's primary business is property and casualty insurance. The company focuses primarily on specialty lines, ranging from areas such as executive liability to commercial equine insurance. The company uses capital generated by its insurance operations to buy noninsurance operations in diverse areas, such as bakery equipment manufacturing and residential homebuilding.